Search details
1.
Defining Endoscopic Remission in Crohn's Disease: MM-SES-CD and SES-CD Thresholds Associated With Low Risk of Disease Progression.
Clin Gastroenterol Hepatol
; 2024 Feb 28.
Article
in English
| MEDLINE | ID: mdl-38428709
2.
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease.
Am J Gastroenterol
; 2024 Feb 09.
Article
in English
| MEDLINE | ID: mdl-38235763
3.
Predictors of Placebo Induction Response and Remission in Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 21(4): 1050-1060.e9, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36029969
4.
Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders.
Clin Gastroenterol Hepatol
; 21(13): 3387-3396.e1, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37391059
5.
Food Processing and Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Clin Gastroenterol Hepatol
; 21(10): 2483-2495.e1, 2023 09.
Article
in English
| MEDLINE | ID: mdl-36731590
6.
Associations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDS With Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology (PURE) Study.
Clin Gastroenterol Hepatol
; 21(10): 2649-2659.e16, 2023 09.
Article
in English
| MEDLINE | ID: mdl-36528284
7.
Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study.
Am J Gastroenterol
; 118(1): 121-128, 2023 01 01.
Article
in English
| MEDLINE | ID: mdl-36066459
8.
REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study.
Am J Gastroenterol
; 118(5): 861-871, 2023 05 01.
Article
in English
| MEDLINE | ID: mdl-36580497
9.
Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn's Disease.
J Clin Gastroenterol
; 57(9): 913-919, 2023 10 01.
Article
in English
| MEDLINE | ID: mdl-36227009
10.
Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission.
Dig Dis Sci
; 68(6): 2658-2666, 2023 06.
Article
in English
| MEDLINE | ID: mdl-36645636
11.
Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study.
Dig Dis Sci
; 68(6): 2635-2646, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37119375
12.
Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD).
Gut
; 71(6): 1078-1087, 2022 06.
Article
in English
| MEDLINE | ID: mdl-33766910
13.
Clinical Decision Support Tool for Infliximab in Crohn's Disease.
Clin Gastroenterol Hepatol
; 20(5): e1192-e1195, 2022 05.
Article
in English
| MEDLINE | ID: mdl-34216825
14.
Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 20(7): 1588-1597.e3, 2022 07.
Article
in English
| MEDLINE | ID: mdl-34329776
15.
Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease.
Clin Gastroenterol Hepatol
; 20(7): 1579-1587.e2, 2022 07.
Article
in English
| MEDLINE | ID: mdl-33838348
16.
Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 20(5): 1095-1104.e9, 2022 05.
Article
in English
| MEDLINE | ID: mdl-34229037
17.
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease.
Am J Gastroenterol
; 117(7): 1106-1117, 2022 07 01.
Article
in English
| MEDLINE | ID: mdl-35435862
18.
Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti-tumor necrosis factor experienced Crohn's disease patients: A propensity-score matched cohort analysis.
J Gastroenterol Hepatol
; 36(10): 2803-2812, 2021 Oct.
Article
in English
| MEDLINE | ID: mdl-34020510
19.
Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial.
Am J Gastroenterol
; 115(8): 1236-1245, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32759621
20.
Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system" by Gui et al.
Gut
; 72(4): 805-807, 2023 04.
Article
in English
| MEDLINE | ID: mdl-35672039